Eli Lilly's experimental drug, lepodisiran, shows promise in reducing lipoprotein(a) levels, a genetic risk factor for cardiovascular disease, in a Phase 2 trial.
Japan warns of a potentially devastating Nankai Trough megaquake that could kill up to 298,000 people and cause massive economic damage.
Eli Lilly's experimental drug, lepodisiran, shows promise in reducing lipoprotein(a) levels, a genetic risk factor for cardiovascular disease, in a Phase 2 trial.
Japan warns of a potentially devastating Nankai Trough megaquake that could kill up to 298,000 people and cause massive economic damage.